Navigation Links
Ampio Pharmaceuticals Announces Closing of Public Offering
Date:7/18/2012

GREENWOOD VILLAGE, Colo., July 18, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ & Zertane™), licensing distribution of these drugs and developing additional new drugs, today announced the closing of a $17,839,120 underwritten public offering of 5,488,960 shares of common stock, including 692,310 shares of common stock which were sold by Ampio and certain of its stockholders pursuant to the exercise of the underwriters' over-allotment option, at a price of $3.25 per share.  Ampio received gross proceeds of $16,912,545 from the offering and the selling stockholders received gross proceeds of $926,575 from the offering.  Ampio will not receive any of the proceeds from the sale of shares by the selling stockholders.

(Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO)

Aegis Capital Corp. and Fordham Financial Management, Inc. acted as joint book-running managers for the offering.

The offering was made pursuant to a shelf registration statement that Ampio filed with the Securities and Exchange Commission ("SEC") and is effective.  The prospectus supplements relating to the offering were filed with the SEC and are available on the website of the SEC at http://www.sec.gov.  Copies of the prospectus supplements relating to the offering may also be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY, 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com or Fordham Financial Management, Inc., 17 Battery Place, South, Suite 643, New York, New York 10004.  

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to a number of risks and uncertainties. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including risks associated with clinical trials, expected results, regulatory approvals, successful commercialization and marketing of Zertane™ and the combination drug in Korea, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contact: Rick Giles, Investor Relations, Ampio Pharmaceuticals, Inc. 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Ampio Pharmaceuticals Schedules 2012 Update Webcast
4. Four-Time Triathlon World Champion Melanie McQuaid Selects Polar USA as Official Heart Rate Training Solution
5. Ampios CEO and CSO Send Message to Shareholders
6. Ampio Pharmaceuticals Announces Proposed Public Offering
7. Ampio Pharmaceuticals Announces Pricing of Public Offering of 4,615,400 Shares of Common Stock
8. Ampio Pharmaceuticals Announces Exercise of Over-Allotment Option
9. Ampio Advances NCE001 Cancer Drug into Preclinical Development Following Successful Recent Financing and the Granting of Patents in USA, Canada, Europe and China
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... DIEGO , April 18, 2017  Astute Medical, ... a case series to be presented at the 2017 ... which begins today and continues through April 22. Physicians ... IGFBP-7 , used to assess risk for acute kidney ... decompensated heart failure (ADHF). Elevated levels ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... ... As a former supermodel known for her timeless beauty, Joan Severance knows ... is that she put all the words in her new book, "Manifest Your Mate: ... and sparkling sense of humor have inspired her to write a book on how ...
(Date:4/24/2017)... ... 24, 2017 , ... Labs often perform the same operations ... operators and management to assess these processes with a critical eye—particularly in the ... , Created with the help of both internal and external process experts, ...
(Date:4/24/2017)... New York, NY (PRWEB) , ... April 24, ... ... students in 72 countries clearly shows that over the last decade, student well-being ... have ticked all the boxes of formal education, join the Islamic State to ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to using ... Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 years, ... USA, and former member of the American Association of Christian Counselors. Rachel studied ...
(Date:4/24/2017)... ... 2017 , ... Miami Periodontist and Dental Implant ... Foundation’s 2017 Symposium on Tissue Regeneration and Implant Dentistry held in Miami Beach ... Symposium at the Fontainebleau Hotel located in Miami Beach, FL. This annual symposium ...
Breaking Medicine News(10 mins):